Drug Trial Radar · NCT03370913
Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)
Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
144
Actual
Start
Dec 19, 2017
Primary completion
Nov 16, 2020
Study completion Nov 20, 2024
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Dec 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP) (from Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit"). The study will also assess the impact of BMN 270 (compared to FVIII prophylaxis) on: the number of bleeding episodes requiring exogenous FVIII treatment in "Post FVIII Prophylaxis to Last Visit", FVIII activity as measured by chromogenic sustrate assay at Week 104 following intravenous infusion of BMN 270, usage of exogenous FVIII replacement therapy in "Post FVIII Prophylaxis to Last Visit", health-related quality of life patient-reported outcomes at week 104 following intravenous infusion of BMN 270. The study will also evaluate the safety of the BMN 270.
Conditions
- Hemophilia A
Interventions
valoctocogene roxaparvovecBiological
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment [Annualized Bleeding Rate (ABR) for All Bleeds] in EEP.Time frame: Baseline to efficacy evaluation period (EEP)
Locations
49 sites in 13 countries. Site status is shown where the registry gives one.
Los Angeles Orthopedic Hospital, Orthopedic Hemophilia Treatment Center
Los Angeles, California
UC Davis Hemophilia Treatment Center
Sacramento, California
University of California San Diego, Hematology and Oncology, Hemophilia &Thrombosis Treatment Center
San Diego, California
UCSF Medical Center
San Francisco, California
University of Colorado
Aurora, Colorado
St. Joseph's Children's Hospital, Center for Bleeding and Clotting Disorders
Tampa, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago, Department of Hematology
Chicago, Illinois
James Graham Brown Cancer Center
Louisville, Kentucky
Tulane University Hematology & Medical Oncology
New Orleans, Louisiana
University of Michigan, Pediatric Hematology and Oncology
Ann Arbor, Michigan
Wayne State University, Detroit Medical Center
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology
St Louis, Missouri
UNC Hemophilia and Thrombosis Center
Chapel Hill, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
The Royal Adelaide Hospital (RAH)
Adelaide, Australia
Royal Brisbane and Women's Hospital
Brisbane, Australia
Alfred Hospital
Melbourne, Australia
Fiona Stanley Hospital
Perth, Australia
Royal Prince Alfred Hospital
Sydney, Australia
University Hospital Leuven
Leuven, Belgium
Campinas Estadual University (UNICAMP) / Campinas Hemocentro / Hematologia E Hemoterapia Center
Campinas, Brazil
Parana's Hematology And Hemotherapy Center (HEMEPAR)
Curitiba, Brazil
Arthur De Siqueira Cavalcanti Hematology State Institute
Rio de Janeiro, Brazil
Sao Paulo University Clinical Hospital
São Paulo, Brazil
Holy Spirit Hematology and Hemotherapy Center
Vitória, Brazil
Regional University Hospital of Lille (CHRU de Lille)
Lille, France
Hopital de la Timone Marseille - Assistance Publique des Hopitaux de Marseille
Marseille, France
Vivantes Clinic im Friedrichshain- Landsberger Allee
Berlin, Germany
University Clinic Bonn
Bonn, Germany
Chaim Sheba Medical Center
Ramat Gan, Israel
Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Center for Hemophilia and Thrombosis Angelo Bianchi Bonomi
Milan, Italy
Charlotte Maxeke Johannesburg Academic Hospital, Hemophilia Comprehensive Care Center
Johannesburg, South Africa
Department of Pediatrics, Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Hospital Teresa Herrera
A Coruña, Spain
University Hospital Virgen del Rocio (HUVR)
Seville, Spain
Changhua Christian Hospital
Changhua, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.